Samsung Electronics Expands its Foundry Capacity with A New Production Line in Pyeongtaek, Korea
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced plans to boost its foundry capacity at the company's new production line in Pyeongtaek, Korea, to meet growing global demand for cutting-edge extreme ultraviolet (EUV) solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200521005844/en/
Samsung Campus in Pyeongtaek, Korea (Photo: Business Wire)
The new foundry line, which will focus on EUV-based 5 nanometer (nm) and below process technology, has just commenced construction this month and is expected to be in full operation in the second half of 2021. It will play a pivotal role as Samsung aims to expand the use of state-of-the-art process technologies across a myriad of current and next generation applications, including 5G, high-performance computing (HPC) and artificial intelligence (AI).
“This new production facility will expand Samsung’s manufacturing capabilities for sub-5nm process and enable us to rapidly respond to the increasing demand for EUV-based solutions,” said Dr. ES Jung, President and Head of Foundry Business at Samsung Electronics. “We remain committed to addressing the needs of our customers through active investments and recruitment of talents. This will enable us to continue to break new ground while driving robust growth for Samsung’s foundry business.”
Following the initial mass production of the EUV-based 7nm process in early 2019, Samsung recently added a new EUV-dedicated V1 line in Hwaseong, Korea, to its global foundry network. With the new Pyeongtaek facility starting full operation in 2021, Samsung’s foundry capacity based on EUV is expected to increase significantly.
Samsung is scheduled to start mass production of 5nm EUV process in the Hwaseong fab in the second half of this year.
With the addition of the Pyeongtaek fab, Samsung will have a total of seven foundry production lines located in South Korea and the United States, comprised of six 12-inch lines and one 8-inch line.
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005844/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)6196-66-3300
Email: ujeong.j@samsung.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Sends Second Public Shareholder Letter to Coway, Urging Announcement of Revised Value-up Plan by January 30, 202615.12.2025 15:54:00 CET | Press Release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway”) since 2023 holding more than 4% of the Company’s outstanding shares through funds it manages or advises, announced that it has sent a second public shareholder letter to Coway’s Board of Directors. The letter calls for measures to address the company’s chronic undervaluation and enhance shareholder value. Align Partners has requested that Coway announce a revised corporate Value-up Plan reflecting these proposals by January 30, 2026. In the letter, Align Partners assessed Coway’s February 2025 plan as insufficient to address Coway’s persistent undervaluation and urged the Board to incorporate seven measures: (1) clear mid-to-long-term valuation and ROE targets with execution plans; (2) clarified and strengthened target capital structure policy; (3) updated shareholder return policy reflecting both the target capital structure policy and new dividend income tax separation regime; (4) en
Marathon Asset Management Provides Junior Capital Financing to EXALTA Group15.12.2025 15:00:00 CET | Press Release
Marathon Asset Management (“Marathon”), a leading global credit manager with more than $24 billion of assets under management, is pleased to announce the closing of a junior capital financing to EXALTA Group (“EXALTA” or the “Company”), a portfolio company of Montagu. Marathon led the financing that supported the formation of EXALTA through the strategic merger of three Montagu-owned companies including Intech, Resolve Surgical Technologies, and Tyber Medical. The transaction marks one of many successful transactions for Marathon’s European Credit business in the healthcare sector, where the firm has a knowledge-based advantage with a dedicated Healthcare Finance business and specialized medical advisory board providing sector insight to middle market companies. EXALTA is a global leader in orthopaedic contract design and manufacturing for spine, trauma, extremities, sports medicine and enabling technology providing comprehensive solutions to OEMs within the medical technology industry
Aurobay Technologies Expands Digital Transformation Partnership With HCLTech to Boost Manufacturing Excellence and Innovation15.12.2025 14:29:00 CET | Press Release
HCLTech, a leading global technology company, and Aurobay Technologies, a division of Horse Powertrain and a global leader in hybrid and low-emission powertrain solutions, have expanded their digital transformation partnership to support Aurobay’s global growth strategy. The expanded partnership establishes HCLTech as Aurobay Technologies’ trusted partner for managing and optimizing SAP, Siemens Teamcenter PLM software and integration services in Sweden and China. This will unlock cost efficiency, operational resilience and digital innovation across Aurobay’s manufacturing and engineering functions by leveraging HCLTech’s flagship service transformation platform, AI Force. The engagement spans core business functions including SAP operations, engineering systems, integration services and mainframe environments, reinforcing Aurobay’s focus on scale, efficiency and seamless operations across global locations. “Horse Powertrain’s division Aurobay Technologies’ digital transformation conti
Applications Now Open for the 5th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award15.12.2025 14:28:00 CET | Press Release
HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE), announced the opening of applications for the 5th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award, offering USD 1 million in prizes. The award seeks to inspire innovative, clean energy–powered solutions for water production, distribution, storage, desalination and purification, supporting global sustainability efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215897854/en/ HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE) - (Photo: AETOSWire) “Since its establishment, Suqia UAE, launched by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has provided clean water to nearly 15 million people in 37 countries worldwide through sustainable development and humanitarian projects.
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press Release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom